Hypertension Management - Complete Textbook Comparison

Kya hai available library mein?

• Harrison's Principles of Internal Medicine, 22nd Edition (2025) - Sabse latest
• Goldman-Cecil Medicine International Edition - Complete reference
• Lippincott Illustrated Reviews: Pharmacology - Drug mechanisms detail mein
• Fuster & Hurst's The Heart, 15th Edition - Cardiology perspective
• Braunwald's Heart Disease - Cardiology specialist text

Note: Davidson's aur P.J. Mehta ki books is library mein available nahi hain. Jo bhi comparison hoga woh upar listed books ke beech hoga - in sab mein Harrison's + Cecil sabse comprehensive hain.

PART 1: DEFINITION aur CLASSIFICATION

Harrison's 22E (2025) ke anusaar:

• Normal BP: <120/80 mmHg
• Elevated: 120-129 / <80 mmHg
• Stage 1 HTN: 130-139 / 80-89 mmHg
• Stage 2 HTN: ≥140/90 mmHg
• Treatment threshold: Zyada tar patients ke liye 130/80 mmHg - kyunki CVD risk 100 mmHg systolic se hi shuru ho jaati hai

Goldman-Cecil Medicine ke anusaar:

PART 2: LIFESTYLE MODIFICATIONS (Non-Pharmacological Treatment)

Goldman-Cecil ke anusaar (Table 64-6):

Harrison's 22E ke anusaar:

1. Unhealthy diet quality
2. Excessive body weight / obesity
3. Excessive dietary sodium (almost sabhi adults WHO limit se zyada lete hain)
4. Insufficient dietary potassium (potassium heart protective hai - stroke risk kam karta hai)
5. Physical inactivity (25%+ U.S. adults koi activity nahi karte)
6. Alcohol consumption

PART 3: PHARMACOLOGICAL TREATMENT - FIRST-LINE DRUGS

Goldman-Cecil Medicine:

1. Calcium Channel Blockers (CCBs)
2. ACE Inhibitors (ACEi) ya Angiotensin Receptor Blockers (ARBs)
3. Thiazide or Thiazide-like Diuretics

Lippincott Pharmacology (Drug mechanism detail):

1. Thiazide Diuretics (Hydrochlorothiazide, Chlorthalidone)

• Mechanism: Shuru mein Na+ aur water excretion badhate hain → intravascular volume kam hota hai → cardiac output aur renal blood flow kam hota hai. Long-term mein peripheral vascular resistance kam karti hain.
• Chlorthalidone preferred over HCTZ (zyada potent, longer acting)
• Contraindication: eGFR <30 mL/min (wahan kaam nahi karte - loop diuretics chahiye)
• Side effects: Hypokalemia, hyperuricemia, hyperglycemia

2. Beta-Blockers (Metoprolol, Atenolol, Nebivolol)

• Mechanism: Cardiac output kam karte hain (heart rate aur contractility ghata ke) + CNS se sympathetic outflow inhibit + renin release kam karte hain → Angiotensin II aur aldosterone bhi kam hota hai
• Selective β1-blockers (metoprolol, atenolol) - asthma patients mein relative contraindication, but non-selective (propranolol) mein absolute contraindication for asthma
• Nebivolol - β1 selective + nitric oxide production badhata hai → peripheral vasodilation bhi
• Use: Especially when concomitant heart disease ya heart failure ho
• Note: Acute heart failure ya peripheral vascular disease mein cautiously use karein

3. ACE Inhibitors (Lisinopril, Enalapril, Ramipril, Perindopril)

• Mechanism: Angiotensin I → Angiotensin II conversion rokta hai → Vasoconstriction nahi hoti, Aldosterone kam nikalta hai, Bradykinin breakdown bhi rokta hai (yahi cough ka reason hai)
• CKD benefits: Glomerular efferent arteriolar vasoconstriction kam karte hain → intraglomerular pressure kam → kidney protection (systemic BP se independent benefit!)
• Side effects: Dry cough (bradykinin se), Angioedema, Hyperkalemia
• Contraindications: Pregnancy (absolute), Bilateral renal artery stenosis, History of angioedema
• Note: ACEi + ARB combination avoid karein (ONTARGET trial evidence - harm)

4. ARBs (Losartan, Valsartan, Telmisartan, Candesartan, Olmesartan)

• Mechanism: Angiotensin II ke AT1 receptor ko block karte hain - same benefits as ACEi but NO cough (bradykinin pathway involved nahi hota)
• Alternative to ACEi when cough ya angioedema ho
• Same contraindications as ACEi for pregnancy aur renal artery stenosis

5. Calcium Channel Blockers (CCBs)

• Warning: Short-acting CCBs (nifedipine immediate release) avoid karein - MI risk increase hota hai
• Dihydropyridines sabse zyada use hote hain hypertension mein kyunki pure vasodilators hain

6. Aliskiren (Direct Renin Inhibitor)

• Mechanism: Renin ko directly inhibit karta hai - RAAS system mein sabse upar kaam karta hai (ACEi/ARB se bhi pehle)
• Combination avoid karein with ACEi ya ARB
• Side effects: Diarrhea, rare cough/angioedema
• Contraindicated in pregnancy, Diabetic patients with ACEi/ARB

PART 4: DRUG SELECTION BY COMORBIDITY (Individualized Therapy)

PART 5: BP TARGETS - Books mein kuch differences hain

Harrison's 22E (2025):

• General population: <130/80 mmHg
• Older adults (≥80 years) - ESC/ESH guideline: BP ≥160 mmHg pe treat karein
• Older adults - American College of Physicians: SBP ≥150 mmHg pe treat karein
• SPRINT trial evidence: SBP <120 mmHg target se CV events kam - but diabetics, stroke history wale, heart failure wale excluded the
• Elderly mein person-centered approach - comorbidities dekhni hain (fall risk, postural hypotension)

Goldman-Cecil:

• General: ≥130/80 mmHg pe treat karein (higher risk individuals)
• Low-risk: ≥140/90 mmHg pe treat karein
• Clinical trial mein <120 mmHg systolic most beneficial, but office target 130/80 mmHg reasonable hai kyunki office BP usually higher hota hai than research settings

Fuster & Hurst's Heart (Cardiology perspective):

• BP control rates suboptimal hain globally - 44% control in 2017-18 (decline from 54% in 2013-14)
• Therapeutic inertia (doctor ka antihypertensive therapy na badhana jab BP high ho) ek major problem hai
• 87% visits mein therapy intensify nahi ki gayi jab BP ≥140/90 tha!

PART 6: RESISTANT HYPERTENSION

Fuster & Hurst aur Cecil dono se:

1. Pseudoresistance (sabse common) - Poor adherence, White coat effect, Incorrect measurement
2. Secondary causes - Primary aldosteronism (11% prevalence in resistant HTN), Sleep apnea, Renal artery stenosis
3. Drug interference - NSAIDs, Cocaine, Oral contraceptives, VEGF inhibitors, Cyclosporine

• Spironolactone (50-100mg/day) - most effective add-on
• Amiloride
• Renal denervation (catheter-based) - newer option, less evidence

Cecil note: 44,644 patients mein se only 15% ko optimal antihypertensive therapy di gayi thi - iska matlab hai ki most "resistant" hypertension actually undertreated hai

PART 7: SECONDARY HYPERTENSION - Screening aur Treatment

PART 8: SPECIAL SITUATIONS

CKD mein Hypertension (Harrison's, block 34):

• First line: Salt restriction (maatra limited ho)
• Drug choice: ACEi or ARBs - glomerular efferent arteriolar vasoconstriction kam karte hain (systemic BP se alag benefit!)
• Warning: eGFR <30% baseline drop acceptable hai (intraglomerular pressure kami ka sign)
• K+ monitoring zaruri hai - Patiromer (K+ binder) use kar sakte hain ACEi ke sath
• SGLT2 inhibitors (gliflozins) - new addition, kidney + cardiac protection dono mein

Pregnancy (Harrison's):

• Gestational Hypertension: New-onset ≥20 weeks
• Chronic Hypertension: Pre-existing or <20 weeks diagnosis
• ACEi, ARB, Aliskiren - teratogenic, absolute contraindication
• Safe drugs: Methyldopa, Labetalol, Nifedipine extended-release, Hydralazine

PART 9: DRUG DOSES - Quick Reference (Cecil, Table 64-7)

Thiazide Diuretics:

• Chlorthalidone: 12.5-25 mg/day (preferred over HCTZ)
• Hydrochlorothiazide: 25-50 mg/day
• Indapamide: 1.25-2.5 mg/day

ACE Inhibitors:

• Lisinopril: 10-40 mg/day OD
• Ramipril: 2.5-20 mg/day OD-BD (cardioprotective evidence)
• Enalapril: 5-40 mg/day OD-BD
• Perindopril: 4-16 mg/day OD-BD (stroke prevention - PROGRESS trial)

ARBs:

• Losartan: 25-100 mg/day OD
• Telmisartan: 20-80 mg/day OD (longest half-life)
• Valsartan: 80-320 mg/day OD
• Olmesartan: 20-40 mg/day OD
• Candesartan: 8-32 mg/day OD

CCBs:

• Amlodipine: 2.5-10 mg/day OD (most commonly used DHP)
• Nifedipine CR/XL: 30-90 mg/day OD
• Diltiazem CD: 120-540 mg/day OD
• Verapamil SR: 120-480 mg/day OD-BD

Beta-Blockers:

• Metoprolol succinate (XL): 25-200 mg/day OD
• Atenolol: 25-100 mg/day OD
• Carvedilol: 12.5-50 mg/day BD
• Nebivolol: 5-40 mg/day OD

PART 10: KEY COMPARISON TABLE - Books ke beech differences

Summary - Sabse important points:

1. Pehle lifestyle modification (DASH diet, Na restriction, exercise, weight loss) - sab books agree
2. First-line: ACEi/ARB + CCB (amlodipine) + Thiazide-like diuretic (chlorthalidone) - near-universal consensus
3. Beta-blockers - first-line se hata diye gaye hain (except compelling indications: IHD, HF, AF)
4. Target: <130/80 for most, personalized for elderly
5. CKD mein: ACEi/ARB mandatory (dual protection - systemic + renoprotection)
6. Black patients mein: CCB + Thiazide preferred (RAAS drugs less effective as monotherapy)
7. Pregnancy mein: ACEi/ARB/Aliskiren strictly contraindicated - safe: Methyldopa, Labetalol, Nifedipine SR
8. Resistant HTN: Spironolactone add karein + secondary causes exclude karein

Recent Evidence Update (PubMed 2024-2025): A 2025 Lancet systematic review (PMID: 40902616) found intensive BP control (<120-130 mmHg) reduces cardiovascular outcomes but increases risk of adverse effects like hypotension/syncope. A 2024 Cochrane review (PMID: 39688187) specifically addresses older adults - evidence for higher BP targets (150 mmHg) in frail elderly remains controversial. Yeh Harrison's ki "person-centered approach for elderly" recommendation ko support karta hai.

Hypertension - Complete Follow-Up Suggestions

(Hypertension ke patient ko kab, kya, aur kaise monitor karein)

SECTION 1: PEHLA DIAGNOSIS KARTE WAQT - Baseline Tests

Routine Lab Tests (Har newly diagnosed HTN patient mein):

Imaging / Cardiac Tests:

SECTION 2: BP MEASUREMENT - Sahi Technique (Follow-Up ka aadhar)

• BP measurements multiple occasions pe leni chahiye, nonstressful circumstances mein:
  • Rest ke baad (5 min)
  • Sitting position, legs crossed nahi
  • Bladder empty
  • Comfortable temperature
• Ek reading pe diagnosis mat karo - jab tak BP >180/120 na ho ya target organ damage ho
• 2+ abnormal readings, preferably weeks ke antar mein leni chahiye diagnosis confirm karne ke liye
• Pseudohypertension elderly mein exclude karo - Osler's sign (cuff inflate karne ke baad bhi artery palpable rahe)

Home BP Monitoring encourage karo:

• Home BP readings office se better correlate karte hain target organ damage ke sath
• Ambulatory BP monitoring sabse accurate hai
• BP logs maintain karne se adherence improve hoti hai

SECTION 3: FOLLOW-UP VISIT SCHEDULE

Katzung's Basic & Clinical Pharmacology ke anusaar:

"Follow-up visits should be frequent enough to convince the patient that the physician thinks the illness is serious. With each follow-up visit, the importance of treatment should be reinforced and questions concerning dosing or side effects of medication encouraged."

Recommended Follow-Up Intervals:

SECTION 4: FOLLOW-UP MEIN KYA ASSESS KAREIN

A. Blood Pressure Control Check:

• Goal: <130/80 mmHg for most patients
• Both arms mein check karein (>10 mmHg difference = subclavian/aortic disease suspect)
• Orthostatic BP check karein (elderly, diabetics) - standing BP measure karein 1-3 min baad

B. Target Organ Damage Assessment (Regular):

C. Side Effects of Antihypertensive Drugs:

D. Drug Adherence Check (MOST IMPORTANT):

1. Poor compliance - sabse pehle check karo
2. Antagonistic drugs - NSAIDs, decongestants, oral contraceptives, cocaine, amphetamines, VEGF inhibitors, cyclosporine
3. High sodium intake - diet history lena
4. High alcohol consumption
5. Secondary causes - consider karo agar previously effective regimen fail ho jaye

SECTION 5: LABS - Follow-Up Frequency

Recommended Annual Labs:

• Serum Creatinine + eGFR - kidney function, especially ACEi/ARB pe
• Serum Potassium - diuretics, ACEi, ARB all affect K+
• Fasting Glucose / HbA1c - thiazides hyperglycemia karte hain
• Urine Albumin-to-Creatinine Ratio (ACR) - early diabetic/hypertensive nephropathy
• Lipid profile - every 1-3 years (CV risk reassessment)

When to Recheck Labs More Frequently:

• ACEi/ARB shuru karne ke 1-2 weeks baad - creatinine/K+ (especially CKD patients)
• Dose increase ke baad
• Renal function deterioration signs ho
• Spironolactone add karne ke baad - K+ closely monitor karein

SECTION 6: GLOBAL CV RISK REASSESSMENT (Annual)

SECTION 7: LIFESTYLE MODIFICATION FOLLOW-UP

SECTION 8: WHEN TO REFER / ESCALATE

Refer to Specialist (Nephrologist/Cardiologist) When:

1. Resistant Hypertension - 3+ drugs at maximum doses including a diuretic, BP still uncontrolled
2. Secondary Hypertension suspected - young patient, abrupt onset, unprovoked hypokalemia, abdominal bruit, episodic symptoms (pheochromocytoma)
3. Target Organ Damage progressive hona - deteriorating kidney function, LV dysfunction
4. Hypertensive Emergency/Urgency - BP >180/120 with organ damage
5. Pregnancy + Hypertension - obstetric + physician team coordination
6. Complex comorbidities - CKD Stage 3+, Severe heart failure, bilateral renal artery stenosis

Emergency (Hospital mein bhejo immediately):

SECTION 9: MEDICATION ADJUSTMENT PROTOCOL

Step-by-step approach:

Step 1: Lifestyle modification trial (1-3 months) - Stage 1, low-risk
   ↓ (if not controlled)
Step 2: Start 1st drug (ACEi/ARB or CCB or Thiazide)
   ↓ (4-6 weeks follow-up - goal mile ya nahi?)
Step 3: If partial response - dose increase OR
         If no response - switch class OR
         Add 2nd drug from different class
   ↓ (4-6 weeks follow-up)
Step 4: If 2 drugs fail - add 3rd drug
   ↓
Step 5: If 3 drugs fail including diuretic = Resistant HTN
         → Add Spironolactone
         → Secondary causes workup
         → Specialist referral

SECTION 10: PATIENT EDUCATION - Follow-Up mein Kya Batayein

1. Disease ka natural history batao - hypertension silent killer hai, symptoms nahi hote
2. Treatment adherence ki importance - "Jab tak BP normal hai tab bhi dawai band mat karo"
3. Drug side effects ke baare mein inform karo - cough (ACEi), ankle swelling (CCBs), etc.
4. Home BP monitoring sikhao - log maintain karo
5. Dosing simplification - OD dosing ke drugs prefer karo compliance ke liye
6. Abrubt stoppage avoid karein - Beta-blockers, Clonidine abruptly band karne pe rebound hypertension
7. Follow-up visits miss na karein - doctor ko serious dikhana hai disease ke baare mein
8. Other CV risk factors control karo - smoking, diabetes, lipids

Summary Table - Follow-Up at a Glance